Recovery & healing peptides

This is the most-searched category on the site and the thinnest in human evidence. Read that sentence again before you read the profiles.

What exists. The preclinical literature here is large and consistent. BPC-157 alone has more than 35 studies, mostly in rodent models of tendon, ligament, muscle, and gut injury. The proposed mechanisms are specific and testable: angiogenesis through VEGFR2, actin regulation through G-actin sequestration, and collagen synthesis through copper transport.

What does not exist. No completed controlled human trial supports a tissue-repair claim for any compound in this category. The human record for BPC-157 is one retrospective report of 12 patients with knee pain and no control group. The human trials linked to TB-500 tested a different molecule. That molecule was full-length recombinant Thymosin β4, given as an eye drop. The European SEER-3 trial failed its primary endpoint. GHK-Cu has real human data, but that data covers topical cosmetic use, not injection.

Two identity warnings. TB-500 is a heptapeptide fragment. Full-length Tβ4 has 43 amino acids. A trial result for one is not a result for the other. GHK-Cu applied to skin and GHK-Cu injected are different exposures with different evidence.

The regulatory position. At its July 2026 meeting, the FDA Pharmacy Compounding Advisory Committee proposed not to add BPC-157, TB-500, or KPV to the 503A bulks list. WADA prohibits BPC-157 under S0 and names TB-500 under S2.